• Effect of docetaxel and celecoxib co-treatment on cell viability of human triple negative breast cancer cells (MDA-MB-231)
  • Elham Miaadi,1,*
    1. Urmia University of Medical Sciences, Urmia, Iran


  • Introduction: Breast neoplasm is one of the most common malignancies. Among different types of breast neoplasm, triple negative breast cancer (TNBC) is more invasive, and survival with this type of cancer cells is less. The present study aimed to investigate the effects of combination treatment with docetaxel (DTX) and celecoxib (CLX) on the cell viability of triple-negative human breast cancer cells (MDA-MB-231).
  • Methods: In this in vitro study, MDA-MB-231 cell line were cultured in RPMI-1640 medium containing 10% FBS. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was performed on the cells to investigate the IC50 of DTX and CLX. Then cell viability percentage of MDA-MB-231 cells was evaluated after combination treatment with DTX and CLX at 24 and 48 hours.
  • Results: The estimated IC50 was 50.22 μM for DTX and 73.95 μM for CLX. The MTT results showed that DTX, CLX, and combined treatment significantly reduced cell viability percentage in 24 and 48 hours.
  • Conclusion: The results of this in vitro study showed that the concomitant use of DTX and CLX is effective in decline of cell viabilty percentage which might be effctive in decreasing of DTX dosage. However, further studies are needed in this field.
  • Keywords: Celecoxib, Docetaxel , MDA-MB-231, Triple Negative Breast Cancer.